ORGN 537 |
Use of site-selective gentamicin derivative in ROCHE-TDM ONLINE Gentamicin Immunoassay
| Mitali Ghoshal, Gerald Sigler, Jane Tsai, Ruth Gerbig, Lili Arabshahi, MyLe Hoang, Andrew Schamerloh, Salvatore J. Salamone, and Joseph Passarelli. Roche Diagnostics Corporation, 9115 Hague Road, Indianapolis, IN 46250 |
| Gentamicin is an aminoglycoside antibiotic that displays broad-spectrum bacterial action for susceptible organisms. At therapeutic serum concentrations ranging from 4 to 10 microgram per milliliter, gentamicin is capable of inhibiting the growth of many gram positive as well as gram -negative bacilli. Because of these characteristics, gentamicin has been most successfully used in treatment of serious infections, especially those caused by gram-negative bacilli. A novel site-selective gentamicin derivative (1) and the corresponding aminodextran conjugate (2) have been prepared. This conjugate (2) is used in the development of Roche-TDM OnLineŽ Gentamicin Assay. The assay format is based on the Kinetic Interaction of Micropaticles in a solution (KIMS) using RD/Hitachi families of automated analyzers. Synthesis of gentamicin derivative (1) and the conjugate (2) will be presented. The results of immunoassays will be discussed.  |
| |
|
Bioorganic, Molecular Recognition, Asymmetric Reactions and Syntheses
11:00 AM-1:00 PM, Wednesday, September 10, 2003 Javits Convention Center -- Hall 1B/1C, Poster
Division of Organic Chemistry
The 226th ACS National Meeting, New York, NY, September 7-11, 2003
|